2024-07-19 18:04:27 ET
Summary
- Bristol-Myers Squibb Company faces challenges with patent expirations and debt from acquisitions, but has strong long-term shareholder return potential.
- Q1 2024 results show revenue growth and promising regulatory approvals, supporting long-term portfolio growth.
- The KarXT acquisition and guidance demonstrate commitment to diversification, managing business, and driving future shareholder returns.
...
Read the full article on Seeking Alpha
For further details see:
Bristol-Myers Squibb - Investors Are Too Long-Term Focused